Netherlands Heart Journal最新文献

{"title":"A stitch in the left main artery.","authors":"Yehia Saleh, Saul Rios, Hussein Shaqra","doi":"10.1007/s12471-025-01950-7","DOIUrl":"https://doi.org/10.1007/s12471-025-01950-7","url":null,"abstract":"","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introducing the 'Transforming cardiology with AI' series.","authors":"Pim van der Harst","doi":"10.1007/s12471-025-01948-1","DOIUrl":"10.1007/s12471-025-01948-1","url":null,"abstract":"","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":"33 4","pages":"111"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of lesion preparation and stent optimisation on lesion-oriented events in PCI with drug-eluting stents: 5-year results from the AIDA trial.","authors":"Mick P L Renkens, Maik J D Grundeken, Laura S M Kerkmeijer, Robin P Kraak, Deborah N Kalkman, Rene J van der Schaaf, Sjoerd H Hofma, Karin E K Arkenbout, Auke P J D Weevers, Karel T Koch, Yoshinobu Onuma, Patrick W Serruys, Jan G P Tijssen, Robbert J de Winter, Joanna J Wykrzykowska, Ruben Y G Tijssen","doi":"10.1007/s12471-025-01937-4","DOIUrl":"10.1007/s12471-025-01937-4","url":null,"abstract":"<p><strong>Background: </strong>Meticulous implantation strategies (i.e. lesion predilatation, stent sizing and postdilatation) are known to decrease lesion-oriented adverse events (LOCE) following percutaneous coronary intervention (PCI) with bioresorbable scaffolds. Their impact on PCI with drug-eluting stents remains unclear.</p><p><strong>Objective: </strong>To assess the impact of meticulous implantation strategies on long-term LOCE in PCI with everolimus-eluting stents (EES).</p><p><strong>Methods: </strong>This substudy of the AIDA trial (NCT01858077) focused on the evaluation of predilatation, stent sizing and postdilatation through analyses of vessel and device diameters at various locations around the lesion. Their interrelations were assessed using quantitative coronary angiography across various lesion locations. Logistic regression was used to evaluate how predictors influenced the primary outcome LOCE, which includes target lesion revascularisation (TLR), target-vessel myocardial infarction (TV-MI) and definite stent thrombosis (ST).</p><p><strong>Results: </strong>LOCE occurred in 84 (7.7%) of 1098 lesions, mainly driven by TLR (63, 5.7%) and TV-MI (46, 4.2%), with ST occurring in 9 (0.8%) lesions. Predilatation and postdilatation were performed in 92 and 49% of lesions, respectively. The difference between the diameter of the predilatation balloon and the reference vessel diameter was significantly associated with an increased risk for LOCE (odds ratio 4.84, 95% confidence interval: 1.91-12.7) with significant interaction with diabetes (p for interaction = 0.04), thus disfavouring predilatation with oversized balloons.</p><p><strong>Conclusion: </strong>The low LOCE rate (7.7%) over 5 years underscores the efficacy of PCI with EES. The use of 'oversized' balloons for predilatation was associated with an increased risk of LOCE by up to fivefold, a risk that was interestingly reduced in patients with diabetes mellitus.</p>","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":"130-137"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving patient-centred decisions in severe aortic stenosis care.","authors":"Judith J A M van Beek-Peeters, Miriam C Faes, Mirela Habibovic, Ben J L Van den Branden, Martijn W A van Geldorp, Nardo J M van der Meer, Mirella M N Minkman","doi":"10.1007/s12471-025-01940-9","DOIUrl":"10.1007/s12471-025-01940-9","url":null,"abstract":"","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":"138-140"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143542611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming cardiology with AI: the eko CORE 500 digital stethoscope.","authors":"Pim van der Harst, Hendrik Nathoe","doi":"10.1007/s12471-025-01952-5","DOIUrl":"10.1007/s12471-025-01952-5","url":null,"abstract":"","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":"33 4","pages":"141-142"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noonan syndrome and parasternal pericardiocentesis.","authors":"Pitt O Lim, May H Ohn","doi":"10.1007/s12471-025-01931-w","DOIUrl":"10.1007/s12471-025-01931-w","url":null,"abstract":"","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":"143-144"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of disease-specific pathways and modifiers in phospholamban R14del cardiomyopathy: rationale, design and baseline characteristics of DECIPHER-PLN cohort.","authors":"Frederik E Deiman, Remco de Brouwer, Lukas Baumhove, Nils Bomer, Niels Grote Beverborg, Peter van der Meer","doi":"10.1007/s12471-025-01941-8","DOIUrl":"10.1007/s12471-025-01941-8","url":null,"abstract":"<p><strong>Background: </strong>Phospholamban (PLN) p.Arg14del (R14del, R14^∆/+) is the most commonly identified pathogenic variant that causes cardiomyopathy in the Netherlands. Many disease characteristics are still unclear, including the phenotypic triggers, disease progression and disease-specific biomarkers. We aim to gain a better understanding of the R14^∆/+ pathophysiology by establishing a cohort across the R14^∆/+ disease spectrum.</p><p><strong>Methods: </strong>The Disease spECifIc PatHways and modifiERs in PhosphoLambaN r14del cardiomyopathy (DECIPHER-PLN) cohort includes 101 participants, categorised as unaffected R14^∆/+ (n = 21), early affected R14^∆/+ (n = 42), end-stage R14^∆/+ (n = 28) and heart failure (HF) of another aetiology (n = 10). R14^∆/+ category was based on left ventricular ejection fraction, HF symptoms, electrocardiogram (ECG) and N‑terminal pro-brain natriuretic peptide concentrations. Of the 91 included R14^∆/+ carriers, 46 (51%) were female, with a mean age of 55 years (standard deviation: 14). Low-voltage ECG older age, arrhythmias, and conduction and repolarisation abnormalities were common in (early) affected R14^∆/+ carriers. Serum and plasma were collected from all participants. Induced pluripotent stem cells were generated from fibroblasts of end-stage R14^∆/+ patients and unaffected R14^∆/+ family members (n = 4) and differentiated into cardiomyocytes. Explanted heart tissue was obtained from R14^∆/+ patients undergoing cardiac surgery and patients with other HF aetiologies as control. Abnormal PLN protein localisation was confirmed in R14^∆/+ carriers.</p><p><strong>Conclusion: </strong>DECIPHER-PLN comprises R14^∆/+ carriers across the disease and non-disease spectrum and can be used to identify disease-specific biological pathways and modifiers that play a role in R14^∆/+ cardiomyopathy. Using a multi-omics approach and in vitro disease modelling, we aim to identify novel biomarkers and improve our understanding of R14^∆/+ pathophysiology. Material is available upon request.</p>","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":"112-119"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PENELOPE 1-year follow-up: legacy effect of a short protocol-led LDL-C-lowering strategy in patients after myocardial infarction.","authors":"Sander van der Brug, Tinka van Trier, Aaram Omar Khader, An-Ho Liem, Astrid Schut, Fabrice Martens, Marco Alings","doi":"10.1007/s12471-025-01939-2","DOIUrl":"10.1007/s12471-025-01939-2","url":null,"abstract":"<p><strong>Objective: </strong>Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of developing atherosclerotic cardiovascular disease (ASCVD). In the PENELOPE study, a guideline-based, protocol-led LDL-C-lowering strategy was applied in patients after myocardial infarction and resulted in 87% reaching target LDL‑C levels of ≤ 1.8 mmol/l within a median of 45 days. This study evaluated PENELOPE's legacy effect on LDL‑C levels after 1 year.</p><p><strong>Methods: </strong>In the PENELOPE study, 999 patients with a myocardial infarction and a history of ASCVD and/or diabetes mellitus were included. If LDL-C > 1.8 mmol/l, lipid-lowering therapy was intensified in three consecutive steps: (1) high-intensity statin (HIST) monotherapy, (2) HIST + ezetimibe, and (3) HIST + ezetimibe + proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i). LDL‑C levels were monitored 4-6 weeks after each step. The primary objective of this study was to assess the prevalence of the LDL‑C target level of ≤ 1.8 mmol/l being maintained after 1 year.</p><p><strong>Results: </strong>Data of 738 patients (74%) were available for 1‑year follow-up. The target LDL‑C level was met in 471 patients (64%). Median LDL‑C levels changed from 1.5 (1.2-1.7) mmol/l immediately after implementation of the protocol-led strategy to 1.6 (1.3-2.0) mmol/l after 1 year. Major treatment regimens were statin (58%), statin + ezetimibe (30%) and PCSK9i + ezetimibe (+ statin) (7%).</p><p><strong>Conclusion: </strong>After a myocardial infarction, implementation of a protocol-led LDL-C-lowering strategy resulted in 87% of patients attaining the LDL‑C target level of ≤ 1.8 mmol/l within a median of 45 (32-77) days. At 1‑year follow-up, 64% maintained this target level and the median LDL‑C increased by 0.1 mmol/l.</p>","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":"120-129"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of late gadolinium enhancement cardiac MRI for ICD therapy in non-ischaemic cardiomyopathy : A 5-year cohort study.","authors":"Luuk H G A Hopman, Marthe A J Becker, Sanna H M de Haas, Anne-Lotte C J van der Lingen, Mischa T Rijnierse, Pranav Bhagirath, Michiel J J M Zumbrink, Louise R A Olde Nordkamp, Lourens F H J Robbers, Marco J W Götte, Vokko P van Halm, Cornelis P Allaart","doi":"10.1007/s12471-025-01946-3","DOIUrl":"https://doi.org/10.1007/s12471-025-01946-3","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the impact of the 2023 Dutch national guidelines for primary prevention implantable cardioverter-defibrillator (ICD) implantation on outcomes in non-ischaemic cardiomyopathy (NICM) patients and to assess the role of late gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMR) in predicting ICD therapy.</p><p><strong>Methods: </strong>This retrospective, single-centre observational exploratory cohort study included patients with NICM who received a primary prevention single-chamber, dual-chamber or subcutaneous ICD between January 2008 and April 2022 and underwent LGE-CMR prior to implantation. Patients were classified into LGE+ and LGE- groups based on the presence of late enhancement detected by CMR. The primary endpoint was time to first appropriate ICD therapy. The secondary endpoint was all-cause mortality.</p><p><strong>Results: </strong>Of the 258 NICM patients in the database, a total of 85 patients were included, of whom 41 had LGE on CMR. After a 5-year follow-up period, appropriate ICD therapy occurred in 20% of the patients in the LGE+ group and 14% of patients in the LGE- group (p = 0.37). All-cause mortality was 7% in the LGE+ group and 14% in the LGE- group (p = 0.46). Multivariable analysis showed no parameters significantly associated with appropriate ICD therapy.</p><p><strong>Conclusion: </strong>Applying the 2023 national guidelines retrospectively on a population of NICM patients with a primary prevention ICD indication demonstrated no significant association between LGE on CMR and appropriate ICD therapy over a follow-up period of 5 years. These findings underscore the need for further research and randomised trials to refine risk stratification and ICD implantation guidelines in NICM, ideally leveraging a multicentre approach to address current limitations in sample size and enhance the generalisability of the results.</p>","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospital-at-Home care for acute heart failure: Feasibility and safety pilot.","authors":"Jesper B Bosman, Florine J P Jager, Erik A Badings, Jan van Wijngaarden, Wouter W Jansen Klomp","doi":"10.1007/s12471-025-01949-0","DOIUrl":"https://doi.org/10.1007/s12471-025-01949-0","url":null,"abstract":"<p><strong>Introduction: </strong>Heart failure (HF) is a global health issue, imposing a significant burden on healthcare systems. Deventer Hospital recently introduced DZThuis, a hybrid Hospital-at-Home care model for patients with acute decompensated heart failure (ADHF). Patients receive treatment with intravenous diuretics at home when possible and in hospital when necessary. This pilot study evaluated the feasibility of DZThuis and compared outcomes with conventional in-hospital care to assess safety.</p><p><strong>Methods: </strong>This retrospective, single-centre cohort study compared 47 DZThuis patients (July 2022-November 2023) with 60 in-hospital ADHF patients admitted between August 2021 and July 2022. Kaplan-Meier curves and log-rank tests were used to analyse mortality and time to the composite endpoint of mortality or HF readmission. Secondary endpoints included total treatment duration, renal function, and complications.</p><p><strong>Results: </strong>No significant differences were found in mortality (p = 0.987) or time to the composite endpoint (p = 0.745). Treatment duration did not significantly differ (DZThuis: 11.3 ± 8.4 days vs in-hospital: 8.8 ± 4.9 days; p = 0.068). Complication rates were comparable. Five DZThuis patients transitioned to in-hospital care, in line with the hybrid model's design.</p><p><strong>Conclusion: </strong>Despite a higher prevalence of comorbidities, DZThuis demonstrated outcomes comparable with traditional in-hospital care for ADHF patients and proved to be a feasible and safe model. Further long-term research in larger cohorts is needed to confirm safety and efficacy, with a particular focus on the impact of Hospital-at-Home care on quality of life and patient satisfaction.</p>","PeriodicalId":18952,"journal":{"name":"Netherlands Heart Journal","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}